Table 1.
Characteristics of the patients with suspected hepatic metastases and adverse events during SEUS
| Characteristics a | No. | Percentage |
|---|---|---|
| Age (median) | 59 years old (41–72) | |
| Menopausal status | ||
| Premenopause | 4 | 17 % |
| Postmenopause | 20 | 83 % |
| Intrinsic subtype | ||
| Luminal phenotype | 9 | 38 % |
| HER2 phenotype | 9 | 38 % |
| Triple negative phenotype | 6 | 25 % |
| Sites of metastases beside liver | ||
| Bone | 17 | |
| Lung | 8 | |
| Distant lymph nodes | 5 | |
| Brain | 3 | |
| Skin-chest wall recurrence | 2 | |
| Treatmentb | ||
| Chemotherapy (+ trastuzumab) | 10 (6) | 42 % |
| Endocrine therapy (+ trastuzumab) | 14 (3) | 58 % |
| Adverse event during SEUS | No. | Grade |
| Nausea | 1 | 1 |
| Vomiting | 0 | |
| Diarrhea | 0 | |
| Edema | 0 | |
| Itching | 1 | 1 |
| Skin rush | 0 | |
| Headache | 0 | 0 |
aThe median follow-up time was 14.1 months (range 9–28 months)
bThe treatment for metastatic disease included chemotherapy with trastuzumab for 6 patients (3 patients were treated weekly with Paclitaxel and 4 patients were treated triweekly with docetaxel), endocrine therapy with trastuzumab for 3 patients, Eribulin was administered to 2 patients and Capecitabine was used to treat 1 patient. The remaining eleven patients underwent endocrine therapy only